search
weight loss drugs
Trends
- 1
A new study suggests that people who discontinue GLP-1 medications, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings add to ongoing debate about how long patients should stay on these widely used weight-loss and diabetes drugs, and whether the cardiovascular benefits persist after stopping treatment.
- 2Doctors weigh in on microdosing Ozempic trend●Is microdosing Ozempic safe? An obesity medicine doctor on the trend, the risks, and when a low dose makes sense
An obesity medicine doctor is addressing the growing trend of taking small, lower-than-prescribed doses of Ozempic, the weight-loss and diabetes drug semaglutide. The expert explains the potential risks of adjusting doses without medical guidance, including reduced effectiveness and side effects, while noting the limited circumstances where a low dose may genuinely make sense for some patients.
- 3
GLP-1 weight-loss drugs such as Ozempic and Wegovy are reshaping sleep medicine, with clinicians reporting improved sleep apnea symptoms in patients losing significant weight and drugmakers seeking apnea indications. Sleep specialists are debating whether medication could reduce reliance on CPAP machines, while researchers caution that long-term effects on sleep disorders remain largely unstudied.
- 4Expert warns high-dose GLP-1 drugs may have wider effects●Functional medicine expert warns high-dose GLP-1 drugs may disrupt more than food cravings
A functional medicine expert has cautioned that high-dose GLP-1 weight-loss drugs such as Ozempic may affect more than appetite and food cravings, suggesting possible broader disruptions to the body that are not yet fully understood. The warning comes as GLP-1 medications continue to surge in popularity for weight loss, with many users reporting unexpected side effects.
- 5Weight-loss jab maker's Vogue World sponsorship sparks concern▼‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event
Novo Nordisk, the maker of weight-loss injection Wegovy, is sponsoring Vogue World, and the partnership is drawing criticism from commentators who call it problematic. Critics argue that having a pharmaceutical weight-loss brand fund a major fashion event risks glamorising slimming jabs and reinforcing harmful body-image pressures in an industry already criticised for promoting thinness.
- 6Fonterra targets nutrition market for weight-loss drug users▼Fonterra cashes in on nutritional needs of those on weight-loss medications
New Zealand dairy giant Fonterra is moving to serve the nutritional needs of people taking weight-loss medications such as GLP-1 drugs, which reduce appetite and can leave users short of protein and key nutrients. The company is positioning high-protein dairy products to fill that gap, tapping into one of the fastest-growing trends in global food and health.
- 7GLP-1 drugs, mental health and exercise in menopause examined●GLP-1's and mental health; exercise and menopause
Public health coverage is drawing together two related topics: the possible mental health effects of GLP-1 weight-loss and diabetes drugs, and the role of exercise for women going through menopause. Listeners are weighing reported mood changes linked to GLP-1 medications against growing evidence that physical activity can ease menopause symptoms such as hot flashes, sleep problems and weight gain.